Yanning Hao

Yanning Hao, Nakissa Sadrieh. FDA CDER analysis of non-human primate (NHP) data in monoclonal antibody (mAb) development to support the streamlining of nonclinical safety studies. Regulatory Toxicology and Pharmacology. 2026;170:106124. doi:10.1016/j.yrtph.2026.106124

Yanning Hao, Tyna Dao, Nakissa Sadrieh. Applications of in vitro new approach methodologies (NAMs) in drug development: A scoping analysis of titles of nonclinical study reports submitted to the FDA. Regulatory Toxicology and Pharmacology. 2026;172:106246. doi:10.1016/j.yrtph.2026.106246